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ttp://dx.doi.org/10.1016/j.ajpath.2013.02.043Brain metastases occur in more than one-third of metastatic breast cancer patients whose tumors over-
express HER2 or are triple negative. Brain colonization of cancer cells occurs in a unique environment,
containingmicroglia, oligodendrocytes, astrocytes, and neurons. Although a neuroinﬂammatory response
has been documented in brain metastasis, its contribution to cancer progression and therapy remains
poorly understood. Using an experimental brain metastasis model, we characterized the brain metastatic
microenvironment of brain tropic, HER2-transfected MDA-MB-231 human breast carcinoma cells (231-BR-
HER2). A previously unidentiﬁed subpopulation of metastasis-associated astrocytes expressing phos-
phorylated platelet-derived growth factor receptor b (at tyrosine 751; p751-PDGFRb) was identiﬁed
around perivascular brain micrometastases. p751-PDGFRbþ astrocytes were also identiﬁed in human brain
metastases from eight craniotomy specimens and in primary cultures of astrocyte-enriched glial cells.
Previously, we reported that pazopanib, amultispeciﬁc tyrosine kinase inhibitor, prevented the outgrowth
of 231-BR-HER2 large brain metastases by 73%. Here, we evaluated the effect of pazopanib on the brain
neuroinﬂammatory microenvironment. Pazopanib treatment resulted in 70% (PZ 0.023) decrease of the
p751-PDGFRbþ astrocyte population, at the lowest dose of 30 mg/kg, twice daily. Collectively, the data
identify a subpopulation of activated astrocytes in the subclinical perivascular stage of brain metastases
and show that they are inhibitable by pazopanib, suggesting its potential to prevent the development of
brain micrometastases in breast cancer patients. (Am J Pathol 2013, 182: 2368e2379; http://dx.doi.org/
10.1016/j.ajpath.2013.02.043)Supported by the intramural program of the National Cancer Institute
(P.S.S.), the Department of Defense Breast Cancer Research Program grant
W81XWH-062-0033 (P.S.S.), GlaxoSmithKline (P.S.S.), the Carlos III
Health Institute (FIS, Madrid) grant ADE09/90041 (F.V.-V.), and the
Burdinola Professorship on Molecular Medicine (F.V.-V.).
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a Material Collaborative Research and Development Agreement with NIH.
Current address of T.A., University of Michigan Medical Scientist
Training Program, Ann Arbor, MI.Breast cancer is the second most common cause of brain
metastasis after lung cancer, occurring in 10% to 15% of
advanced patients and in approximately 30% of autopsies.1,2
Risk factors for the development of brain metastases include
young patient age, large primary tumors, multiple positive
lymph nodes, and hormone receptor negativity.3 In addition,
the incidence of brain metastasis appears to be increasing
because of the introduction of more sensitive diagnostic
methods and improved therapies, the latter particularly in
patientswithHER2-overexpressingmetastatic breast cancer.4
The standard of care for brain metastases is palliative, and in
most cases chemotherapy is ineffective.5,6 New drugs that arestigative Pathology.
.both brain permeable and prevent speciﬁc pathogenic mech-
anisms of the brain metastasis process have been identiﬁed in
preclinical experiments but await appropriate clinical trials.7e11
PDGFRbþ Astrocytes and Brain MetastasisThe cancer microenvironment is of crucial importance
for a complete understanding of the disease12e15 because it
is the interface between cancer cells and pathophysiology
of the patient.16 The brain represents a unique microenvi-
ronment for epithelial cancers that remains to be further
investigated. Salient features include the blood-brain bar-
rier that surrounds the vasculature and protects the brain
from unwanted substances and leukocyte inﬁltration, and
a rich cellular milieu, including neurons, pericytes, and
glial cells. Because the brain is critical for both cognitive
and physical function, microenvironmental changes during
cancer metastasis may adversely affect the patient. A better
understanding of the brain microenvironment during me-
tastasis may contribute to development of more effective
therapeutics.
Relatively little is known about the microenvironment of
brain metastases of breast or other cancers. Most of our
information comes from experimental models of brain
metastasis in which brain tropic lines are introduced into the
circulation of mice via the left cardiac ventricle or carotid
artery and then colonize the brain over a several-week peri-
od.17e20 In the 231-BR model system, cancer cells extrava-
sate the circulatory system and bind to the surrounding
basement membrane through b1 integrin; in this microenvi-
ronment, cancer cells move and proliferate along the outside
of the blood vessels.21 During the subclinical stage of the
brain metastasis process, where injury is subtle but consis-
tent, a continuous neuroinﬂammatory response involves
activation of astrocytes and microglia, identiﬁed by expres-
sion of glial ﬁbrillary acidic protein (GFAP) and F4/80 or
CD11b/CD45, respectively.21e23 This neuroinﬂammatory
response is also observed in clinical samples from resected
human brain metastases in which reactive astrocytes and
microglia both surround and inﬁltrate the metastatic lesion,
validating experimental observations.22 In coculture
experiments, glial cells increased the number of colonies
formed in soft agar by 231-BR cells by ﬁvefold,22 and
astrocytes also increased cancer cell proliferation and up-
regulated the expression of survival genes,24,25 suggesting
mechanistic contributions of microenvironmental cells to
brain metastasis.
Consistent with what has been reported for other organs,
platelet-derived growth factor (PDGF)-B is also a key
protective factor in noncancerous brain damage,26,27 con-
tributing to blood-brain barrier stability, angiogenesis, and
vascular remodeling through the activation of PDGF
receptor b (PDGFRb)-expressing brain pericytes and neuro-
glial progenitor cells.28,29 During cancer progression
PDGFRb expression has long been associated with tumor-
associated stromagenic and angiogenic activities.30 However,
its role during brain metastasis development is unknown.
In this article, we characterize the neuroinﬂammatory
microenvironment of a breast cancer experimental brain
metastasis model system (231-BR cells transfected with
HER2; 231-BR-HER2) and identify a novel subpopulation
of metastasis-activated astrocytes that express an activeThe American Journal of Pathology - ajp.amjpathol.org(phosphorylated) form of PDGFRb (p-PDGFRb). The exis-
tence of this novel subset of astrocytes was conﬁrmed in
resected specimens of human brain metastasis from ﬁve
patients with HER-2eoverexpressing breast cancer, two
patients with lung cancer, and one patient with colorectal
cancer. Importantly, we demonstrate that primary cultured
human astrocytes expressed (activated) p-PDGFRb in res-
ponse to tumor-derived soluble factors. We previously re-
ported that pazopanib, an inhibitor of vascular endothelial
growth factor receptors, PDGFRs, c-kit,31 and B-Raf19,32
prevented brain metastasis formation in the 231-BR-HER2
model by 73%, targeting B-Raf activation in the tumor cells.19
Herein, we show that pazopanib also inhibited the activation
of p-PDGFRbeexpressing astrocytes in the experimental
brain metastasis model and in tumor-activated astrocytes
in vitro. Our results indicate that brain-permeable drugs can
target both tumor cells and the neuroinﬂammatory microen-
vironment in the brain metastatic process.
Materials and Methods
Drugs
Pazopanib was provided by GlaxoSmithKline (London,
United Kingdom) through a Material Collaborative Research
and Development Agreement with NIH. For in vitro exper-
iments, pazopanib was reconstituted in dimethyl sulfoxide
(DMSO) and stored at 80C.
Cell Lines and in Vitro Culture Conditions
The human MDA-MB-231-BR brain-tropic line (231-BR)
transfected with HER2 (231-BR-HER2) was previously
described.17 Conditioned medium from 231-BR-HER2 cells
was prepared as follows: 5  106 subconﬂuent-growing
231-BR-HER2 cancer cells were incubated in 10 mL of
serum-free RPMI 1640 medium, in a 75-cm2 ﬂask, for
12 hours. Supernatant ﬂuids were then collected, centrifuged
at 2500  g for 3 minutes, supplemented with 50% fresh
serum-free medium, and run through a 0.22-mm ﬁlter before
being used. A human immortalized astrocyte line33 was
kindly provided by Drs. Jayne Stommel (National Cancer
Institute, Bethesda, MD) and Russell O. Pieper (University of
California, San Francisco, CA) andmaintained in Dulbecco’s
modiﬁed Eagle’s medium (Invitrogen, Carlsbad, CA) sup-
plemented with 10% fetal bovine serum.
Tumor Tissue
All tumor specimens used in this study were obtained from
patients with cancer undergoing medically indicated neuro-
surgical treatment after written consent in accordance with
the appropriate clinical protocol. Tissue collection was
approved by the Institutional Review Board/Comité Ético de
Investigación Clínica of the Hospital of Madrid Scientiﬁc
Foundation (Madrid, Spain). In total, eight tissue samples2369
Gril et alfrom brain metastases (ﬁve from breast cancer, two from lung
cancer, and one from rectal cancer) were used. The diagnosis
was histopathologically veriﬁed, and their clinicopatholog-
ical information is reported as Supplemental Table S1. The
material obtained was snap-frozen in liquid nitrogen and kept
at 80C. Five micron-thick tissue sections were cut, dried
for 5 minutes, and then ﬁxed in ice-cold acetone for
10 minutes. The sections were then dried for 15 minutes and
stored at 20C. Before staining, the sections were thawed
and rinsed in phosphate buffered saline (PBS).
Isolation and Primary Culture of Human Glial Cells
Brain tissue from a tumor-unaffected area obtained during the
neurosurgical procedure of brain tumor removal was dis-
aggregated mechanically by cutting the tumor into small
pieces and enzymatically with Accumax (Millipore, Billerica,
MA). Dissociated cells were resuspended in Neurobasal
media (Life Technologies, Carlsbad, CA) supplemented with
10% heat-inactivated fetal bovine serum, L-glutamine, anti-
biotics (100 U/mL penicillin; 0.1 mg/mL streptomycin), and
plated into 25-cm2 culture ﬂasks. During the initial estab-
lishment of cultures, 2.5mg/mL Fungizone (Gibco-Invitrogen,
Carlsbad, CA) was also added to the culture medium. The
culture medium was replaced every 4 days. Primary cultures
were grown to conﬂuence (70% to 90%), and further astrocyte
enrichment of the glial cell culture was obtained by placing the
ﬂask on a shaker for 12 to 14 hours at 250 rpm; mainly as-
trocytes remained adhered to the ﬂask. The medium with
detached neurons and glial cells was removed. Astrocyte-
enriched glial cell cultures were checked for existing cell
phenotypes with the use of the following markers: Olig2,
neuron/glial antigen 2 (NG2), GFAP, CD11b/CD18.
Cell Viability Assay
The human immortalized astrocytes were plated at a density of
2000 cells/well in 96-well plates and incubated overnight to
allow cells to adhere. Astrocytes were maintained in 10% fetal
bovine serum and treated with increasing concentrations of
pazopanib (0.5, 1, 2, 4, 6, 8, and 10 mmol/L), or with DMSO as
a control, for 120 hours. The number of viable cells was
determined by addingMTT (Sigma-Aldrich, St. Louis,MO) at
a ﬁnal concentration of 0.5 mg/mL to each well for 4 hours.
After incubation, MTT was dissolved in DMSO, and absor-
bance was measured at 570 nm. Results are representative of
three independent experiments, each performed in quintuplicate.
Immunostaining of Cultured Glial Cells
Chamber slides (Lab-Tek, Thermo Scientiﬁc, Waltham, MA;
ref. 154526) were coated with laminin at 10 mg/mL for 1 hour
at 37C. Both the human astrocyte-enriched glial cell primary
culture and immortalized astrocytes were seeded in chamber
slides at 0.5  104 cells per chamber for 48 hours to allow
cells to adhere. Human immortalized astrocytes were serum-2370starved overnight and subsequently treated with DMSO or
5 mmol/L pazopanib for 24 hours, then retreated for an
additional 24 hours. Human astrocyte-enriched glial cells
were maintained in Neurobasal medium or incubated in
tumor-activated medium with DMSO or pazopanib for
18 hours. Both type of astrocyte cultures were washed twice
with PBS and ﬁxed with 4% cold paraformaldehyde for
10 minutes. After two washes with PBS for 5 minutes, cells
were incubated with blocking buffer (PBS plus 5% goat
serum and 0.2% Triton X-100) for 1 hour, then with anti-
PDGFRb phosphotyrosine 751 (p751-PDGFRb; dilution
1/50; Santa Cruz Biotechnology, Santa Cruz, CA) or rabbit
anti-GFAP (dilution 1/300; Dako, Carpinteria, CA) in the
same blocking buffer for 2 hours at room temperature. After
three 5-minute washes with PBS, cells were incubated with
Alexa 488-conjugated secondary antibody (Invitrogen) and
200 mg/mL DAPI for 1 hour at room temperature. Sections
were mounted in Fluorescent Mounting Medium (Dako)
and photographed with an Axioskop microscope with an
Axiocam digital camera (Carl Zeiss Microimaging, Jena,
Germany). AxioVision software version 4 was used for
image acquisition and quantiﬁcation.
Immunostaining of Brain Tissue from Mouse and from
Patient Brain Metastatic Tissues
The mouse experiments were described previously and were
conducted under an approved animal use agreement with the
National Cancer Institute.19 For the tissues from the mouse
model, immunostaining was performed on 10-mm thick
sections of immediately frozen tissue in Optimal Cutting
Temperature compound. Sections were ﬁxed and per-
meabilized in ice-cold methanol or ice-cold acetone or were
ﬁxed with paraformaldehyde 4% (depending on the anti-
body), and the sections were preblocked in PBS containing
goat serum, 5% and 0.2% Triton X-100 for 1 hour to per-
meabilize. Subsequently, the ﬁrst and the secondary anti-
bodies were incubated in the same PBS solution. The
following antibodies were used: rat anti-mouse CD31 (dilu-
tion 1/500; BD Pharmingen, San Diego, CA), mouse anti-
human cytokeratin MNF116 (dilution 1/50; Dako), rabbit
anti-mouse NG2 (dilution 1/200l Millipore), rabbit anti-
mouse Collagen type IV (dilution 1/500; Millipore), mouse
anti-human desmin (dilution 1/50; Dako), rat anti-mouse
CD11b (dilution 1/50; Millipore), rat anti-mouse CD45
(dilution 1/200; Millipore), rabbit anti-human GFAP ready to
use (Dako), mouse anti-human GFAP (dilution 1/100; Milli-
pore), rabbit anti-mouse PDGFRb phosphotyrosine 751
(dilution 1/50; Santa Cruz Biotechnology and Cell Signaling
Technology, Danvers, MA), and rabbit anti-mouse PDGFRb
phosphotyrosine 1021 (dilution 1/50; Santa Cruz Biotech-
nology). First antibodies were incubated for 2 hours at room
temperature. Alexa 546-conjugated or Alexa 488-conjugated
secondary antibody (Invitrogen) was used; 200 mg/mL DAPI
was added to the secondary antibody mixture and incubated
for 1 hour at room temperature. Sections were mounted inajp.amjpathol.org - The American Journal of Pathology
PDGFRbþ Astrocytes and Brain MetastasisFluorescent Mounting Medium (Dako) and photographed by
using an Axioskop microscope with an Axiocam digital
camera (Carl Zeiss Microimaging). AxioVision software
version 4 was used for image acquisition and quantiﬁcation.
To quantify p751-PDGFRbeexpressing astrocytes and
CD11b/CD45-expressing microglia, all lesions within one
brain section per mouse, from ﬁve to seven mice per group,
were analyzed. Two measures were performed: the number
of positive cells per group of metastases and the percentage of
area covered by the imunostaining.
Flow Cytometry on p751-PDGFRbeExpressing Cells
Astrocyte-enriched glial cell cultures were incubated for
18 hours with either Neurobasal medium or 50%-diluted
tumor-conditioned medium (from 231-BR-HER2 cells cul-
tured in serum-free basal conditions and prepared as described
in Cell Lines and in Vitro Culture Conditions.) in the presence
of 5 mmol/L pazopanib or 0.025% DMSO (vehicle). Cells
were then analyzed by ﬂow cytometry with the use of a FACS
Vantage SE ﬂow cytometer (Becton Dickinson, Madrid,
Spain) by using a wavelength analysis (green-ﬂuorescein iso-
thiocyanate, 530 nm) after excitation with 488-nm light. p751-
PDGFRbeexpressing intensity was expressed as the logarithm
of the speciﬁc green ﬂuorescence. Data were represented as
average intensity values for live cells. Dead cells (<10%) were
excluded from all of the analysis with the use of Viaprobe
(Becton Dickinson).
Statistical Analysis
We performed either a two-factor factorial or weighted
mixed model analysis of variance on the data as appropriate.
For the ratio of p751-PDGFRB to DAPI intensity data, we
performed a two-factor (experiment, treatment) analysis of
variance (ANOVA) on transformed data (4Oy as indicated by
the Box-Cox transformation). The experiment by treatment
interaction effect was dropped from the model if P> 0.05. For
the percentage of cells expressing p751-PDGFRB data, we
compared distributions with the use of the exact version of the
Wilcoxon rank sum test. For the number of p751-PDGFRþ
astrocytes and percentage of p751-PDGFRþ astrocytes cov-
erage data, we performed a weighted mixed model ANOVA
on transformed data [Oy and log10(y), respectively, per Box-
Cox transformation]. The total surface area was used as the
weight for each observation,micewere speciﬁed as the random
effect, and dosewas theﬁxed effect. ANOVA-based two-tailed
t-test P values were adjusted with Dunnett methods. For
the number of CD11b/CD45þ microglia and percentage of
CD11b/CD45þ microglia coverage data, we used the same
methods as described in this paragraph for the p751-PDGFR
astrocytes data. For the percentage of GFAPþ astrocyte
coverage data, we compared distributions with the use of the
exact version of theWilcoxon rank sum test. For all ANOVAs,
residuals were examined for normality and homogeneity and
were partitioned if found to be heterogeneous.The American Journal of Pathology - ajp.amjpathol.orgResults
Architectural and Microenvironmental Features of the
Brain Colonization Process of 231-BR-HER2 Breast
Cancer Cells
Brain micrometastases were studied on day 21 after left cardiac
ventricular injection of 231-BR-HER2 cells. In Figure 1, A and
B, 231-BR-HER2 cells were stained with anti-human cytoker-
atin antibody (green) to verify the human origin of cytokeratin-
expressing perivascular cells, and the brain microvasculature
was stained with anti-murine CD31 antibody (red). Metastatic
cancer cells almost exclusively located and grew around brain
microvasculature from gray matter but some deposition also
occurred at the interface of gray and white matter as well.
Interestingly, micrometastases did not develop as pushing-type
growth nodules. Instead, they formed a widespread microvas-
cular ensheathment that progressively expanded as a layer
around and along brain microvessels, without any evidence of
parenchymal inﬁltration and neoangiogenesis, which altered
normal brain microvascular architecture.
In Figure 1, CeM,DAPI was used to study the perivascular
growth pattern of 231-BR-HER2 cells in combination with
markers for the main components of the normal blood-brain
barrier, including endothelial cells (anti-CD31), basement
membrane (anti-collagen IV), pericytes, and progenitor glial
cells (anti-NG2), smooth muscle cells (anti-desmin) and
astrocyte branching and feet (anti-GFAP). As shown in
Figure 1, CeE, perivascular development of metastatic cells
remarkably altered the blood-brain barrier structure. NG2
(nerve/glia antigen, chondroitin sulfate proteoglycan), which is
expressed by immature pericytes34 and oligodentrocyte
progenitors35 was associated with CD31-expressing vessels,
and their number remarkably increased at microvascular
segments surrounded by cancer cells. Moreover, as shown in
Figure 1C, brain microvessels costained by NG2 and CD31
were smaller and thinner in tumor-unaffected areas compared
with intrametastatic microvascular segments. The muscle cell-
speciﬁc class III intermediate ﬁlament34 desmin, usually used
as a marker of mature pericytes, appeared to follow the same
distribution as the CD31 and NG2 staining (Figure 1D). Some
of the NG2-expressing pericytes also coexpressed desmin
(Figure 1E), conﬁrming themesenchymal nature of those cells.
Collagen IV distribution (Figure 1, F and G, and
Supplemental Figure S1) in this brain metastasis model was
colocalized with CD31-expressing vessels from both tumor-
unaffected and -metastasized areas, suggesting that basement
membrane collagen was preserved around any brain capillary.
However, collagen IV also formed a well-deﬁned layer around
perivascular metastases, in the limit between cancer cells and
normal brain parenchyma (Figure 1, F and G). Therefore,
collagen IV delineated the cancer cell territory between an
inner layer at intrametastatic capillaries and an outer layer
around metastatic tissue between cancer and normal brain
parenchyma. In larger metastases, residual collagen IV can be
observed (Figure 1F and Supplemental Figure S1).2371
Figure 1 Characterization of themicroenvironment of the 231-BR-HER2 brainmicrometastases. Brain sections were immunostainedwith different markers to analyze
the microenvironmental structure aroundmicrometastases.A and B: Metastatic 231-BR-HER2 cells (human cytokeratin; green) grew along brain microvessels (CD31, red).
B: Highermagniﬁcation ofboxed area inA. CeM: Clusters of cells stainedwith DAPI (blue) underwent 231-BR-HER2micrometastases. Individual dots are neuronal nuclei.
C: Brain microvessel (CD31, red) coverage by NG2-expressing pericytes (green), surrounded by 231-BR-HER2 cancer cells (large white arrow). The thin white arrow
indicates NG2-covered blood vessels in normal brain area. D: Micrometastases grew along desmin-expressing pericytes (green). E: NG2-expressing pericytes (green) and
desmin-expressingpericytes (red) showed the same localizationpattern. F andG: Collagen type IV-expressingbasementmembranes (green) aroundbothbrainmicrovessels
(CD31, red) andperivascular cancer cells, forming the inner andouter limits (largewhitearrows)ofbrainmicrometastases. The thinwhitearrow indicates residual collagen
IV.H: CD11b and CD45 double-staining for reactive microglia/macrophages (red) located around metastases. I: Some CD3-expressing lymphocytes (green;white arrows)
were observed near micrometastatic clusters (CD31, red). J: Hypertrophic reactive GFAP-expressing astrocytes (green). K: 231-BR-HER2 metastases (DAPI) grew around
pericytes from brain microvessel (NG2, green) and was surrounded by GFAP-expressing astrocytes (red). L: Microvessel-associated NG2-expressing pericytes (green) sur-
rounded by GFAP-expressing astrocytes (red).M: p751-PDGFRbeexpressing cells localized only aroundmicrometastases (cluster of DAPI-stained cells). Brain microvessels
were visualized with anti-CD31 antibody (red). Scale bars: 200 mm (A and B); 50 mm (CeJ, L, and M).
Gril et alConsistent with our previous observations,22 we also
detected CD11b-CD45 coexpressing cells around, but not
inside, micrometastases, indicating reactive microglia recruit-
ment to the vicinity of cancer cells (Figure 1H). However,
few single CD3þ lymphocytes were observed (Figure 1I),
suggesting limited lymphocyte inﬁltration in the metasta-
sized brain at this early stage.
Another remarkable glial cell type that surrounded, but not
inﬁltrated, metastatic tissue was represented by GFAP-
expressing cells (Figure 1J). These cells were most probably
of astrocyte nature and also delineated an outer layer of
tumor cell growth from the microvessels (Figure 1K).2372Compared with highly stellated phenotype of astrocytes from
tumor-unaffected brain areas (Figure 1L), perimetastatic
astrocytes were low stellated (Figure 1K). These GFAP-
expressing cells were NG2 negative and unrelated to axonal
ﬁbers, discarding their oligodendroglial nature.
A Subpopulation of Brain Metastasis
Microenvironment-Associated Astrocytes Express
Activated PDGFRb
With the use of an antibody to p751-PDGFRb we noticed
a previously undescribed population of neuroinﬂammatory cellsajp.amjpathol.org - The American Journal of Pathology
Figure 2 Identiﬁcation of metastasis-associated astro-
cytes expressing p751-PDGFRb. A: p751-PDGFRbeexpressing
cells are located near 231-BR-HER2 experimental micro-
metastases. B: Brain tissue sections were costained with GFAP
(red) to detect reactive astrocytes with p751-PDGFRb (green).
C: p751-PDGFRbeexpressing cells (green) were distinct from
reactive microglia (CD11b/CD45, red). D: p751-PDGFRbþ cells
(green) were distinct from desmin-expressing cells (red).
E: p751-PDGFRbeexpressing cells (green) (antibody from
Santa Cruz Biotechnology) and GFAP-expressing astrocytes
(red). F: p751-PDGFRbeexpressing cells (green) (antibody
from Cell Signaling Technology). G: p1021-PDGFRbeexpressing
cells (green). HeK: Immunostaining of a brain metastasis
tissue section from a biopsy of a patient with stage IV breast
cancer. Same antibodies were used as above. DAPI staining in
blue (H). Some p751-PDGFRbeexpressing cells in green (I)
and GFAP-expressing cells in red (J) are colocalized in
yellow (K). Scale bars: 100 mm (A, B, and D); 50 mm (C);
20 mm (EeG); 40 mm (HeK).
PDGFRbþ Astrocytes and Brain Metastasiswith a structure indicative of astrocytes, but positive staining
for this activated growth factor receptor (Figures 1M and 2A).
To conﬁrm the astrocytic lineage of these cells, dual staining
with antiep751-PDGFRb and GFAP was conducted
(Figure 2B). In addition, the p751-PDGFRbeexpressing
astrocytic cells were negative for microglial and pericyte
markers in other coimmunoﬂourescence studies (Figure 2, C
and D, respectively). To eliminate the possibility that astro-
cytic p751-PDGFRb expression was an artifact of an
antibody cross reactivity, the staining obtained with the p751-
PDGFRb antibody initially used (Figure 2E) was compared
with the staining obtained with two other antibodies: an
independent polyclonal antibody against the same phospho-
tyrosine 751 of PDGFRb (Figure 2F) and a polyclonal
antibody against the phosphotyrosine 1021 of PDGFRb
(Figure 2G). The three antibodies gave the same pattern of
staining, exclusively in the vicinity of metastatic cells, further
supporting that phosphorylated PDGFRb expression was
a speciﬁc feature of the astrocyte neuroinﬂammatory response
around perivascular brain micrometastases.
We next askedwhether a subpopulation of p751-PDGFRbþ
astrocytes is found in human brain metastases. Sections from
eight craniotomy specimens were stained with p751-PDGFRb
and GFAP antibodies. Five brain metastatic tissues were from
patients with stage IV HER-2eoverexpressing breast cancer,
with estrogen receptore and progesterone receptorenegativeThe American Journal of Pathology - ajp.amjpathol.orginvasive ductal breast cancers. To determine whether the
presence of this p751-PDGFRbþ astrocyte population was
generalizable to different brain metastases, craniotomy speci-
mens from two patients with small cell lung adenocarcinoma
and one with a colorectal adenocarcinoma were also stained
and analyzed (Supplemental Table S1). In all cases, metastatic
lesions showed undeﬁned boundaries and tended to invade
the surrounding parenchyma as single cancer cells. An
extensive GFAP staining around metastatic lesions was also
observed in all cases, which was indicative of reactive gliosis.
In addition, someGFAP-expressing cells also expressed p751-
PDGFRb, particularly near intrametastatic microvessels. A
representative brain metastasis from breast cancer is shown in
Figure 2, HeK. Most GFAP-expressing astrocytes that
decorated the tumor cells coexpressed p751-PDGFRb. The
data indicate that, in both an experimental model system and
human craniotomy specimens, PDGFRb activation is a feature
of tumor-activated astrocytes.
Pazopanib Inhibits PDGFRb Phosphorylation in Human
Astrocytes in Vitro and ex Vivo
We previously reported that pazopanib, an inhibitor of
vascular endothelial growth factor receptor, PDGFR, c-kit,
and B-Raf activities, prevented the formation of experi-
mental brain metastases by 231-BR-HER2 cells by 73% and2373
Gril et alof MCF7-HER2-BR3 cells by 55%.19 The major target for
pazopanib in the tumor cells appeared to be B-Raf, based on
a reduction in tumor cell pErk but not microvessel density
in vivo. Given the presence of activated PDGFRb in the
astrocytic neuroinﬂammatory response, we asked whether
pazopanib modulated PDGFR activation in these cells.
In vitro studies were conducted with human immortalized
astrocytes (immortalized by expression of the protein E6 and
E7 form the human papillomavirus33). These cells uniformly
expressed p751-PDGFRb under basal culture conditions.
The addition of 5 mmol/L pazopanib to the culture medium for
48 hours decreased p751-PDGFRb by 71.2% (difference
between medians) compared with DMSO control culture
(P< 0.0001) (Figure 3,AeC).UsingMTTviability assays, the
concentration that inhibited 50% of pazopanib activity was 9
mmol/L after 120 hours of incubation (data not shown). This
concentration compared favorably to its concentration that
inhibited 50% of tumor cells in vitro.32 The data suggest that
pazopanib can deactivate and inhibit the proliferation of acti-
vated PDGFRb-expressing astrocytes.
To extend these observations past an immortalized astrocyte
cell line, short-term primary cultures of astrocyte-enriched glial
cells were prepared from fresh craniotomy specimens from
ﬁve different patients. Figure 3, DeG, presents representative
immunoﬂuorescence staining of these cultures, showing col-
ocalization of p751-PDGFRb and GFAP. PDGFRb activation
was stable through short-term culture. Medium from 231-BR-
HER2 cell cultures was harvested as a tumor-conditioned
medium, mimicking the brain metastasis microenvironment,
and added to the primary astrocyte cultures. Four different
conditions were performed: incubation with Neurobasal
medium containing pazopanib or DMSO, or incubation with
tumor-conditioned medium containing either pazopanib or
DMSO, for 18 hours (Figure 3H). The tumor-conditioned
medium increased the median number of p751-PDGFRbe
expressing primary astrocytes by 23.2% compared with Neu-
robasal medium culture (Figure 3H). The data outline a tumor
cellemicroenvironmental interaction in the brain where tumor-
derived soluble factors induced p751-PDGFRbeexpressing
astrocytes. Pazopanib decreased the basal level of p751-
PDGFRb expression in normal medium from a median of
21.98% to 12.47%, or a 43.4% decrease. A greater decrease was
observed in tumor-activated cultures, with pazopanib inducing
54.6% reduction in the intensity of p751-PDGFRb.
Prevention of 231-BR-HER2 Brain Metastasis
Formation Is Associated with Pazaponib Inhibition of
p751-PDGFRbþ Astrocytes in Vivo
In previously reported studies, the 231-BR-HER2 cell line
was injected into the left cardiac ventricle of immunocom-
promised mice, and, beginning 3 days after injection, mice
were treated twice daily by oral gavage for 21 days with
vehicle or with 30 or 100 mg/kg pazopanib. To determine the
effect of pazopanib on the neuroinﬂammatory response,
sections of brains from ﬁve mice per treatment group2374were examined for p751-PDGFRbeexpressing astrocytes
(Figure 4). Pazopanib signiﬁcantly inhibited the number of
p751-PDGFRbeexpressing astrocytes from a median of
324.6 positive cells in vehicle-treated mice to 98.1 and 101.3,
producing 69.8% and 68.8% decrease at 30 and 100 mg/kg,
respectively (P Z 0.023 and P Z 0.022, respectively)
(Figure 4A). The surface area covered by p751-PDGFRbþ
astrocytes was also measured by image analysis, and pazo-
panib treatment resulted in a 64.9% and 75.2% decline in the
percentage of p751-PDGFRbeexpressing astrocytes, at 30
and 100 mg/kg, respectively [a median 4.44% of the area
covered by p751-PDGFRbþ astrocytes in vehicle-treated
mice compared with 1.56% (P Z 0.13) and 1.10% (P Z
0.070) for 30 and 100 mg/kg pazopanib, respectively].
Figure 4, CeE, shows representative images of p751-
PDGFRbeexpressing astrocytes in the vicinity of metas-
tases at the three different treatments (vehicle, 30 mg/kg, and
100 mg/kg, respectively). Serial tissue sections from the
same mice used to quantify p751-PDGFRbeexpressing
astrocytes were immunostained with a GFAP antibody to
evaluate the effect of pazopanib on the general population of
astrocytes. Virtually all of the astrocytes expressed GFAP,
but an increase in expression was observed in the astrocytes
near the metastases. Pazopanib induced only a minor
decrease in the number for GFAPþ astrocytes (Supplemental
Figure S2). Because the GFAP-overexpressing astrocyte
population was not signiﬁcantly decreased by pazopanib, this
observation suggests that pazopanib might not kill astrocytes
but rather prevent their activation. As a control, microglial
activation was analyzed and quantiﬁed in the same manner.
Pazopanib treatment did not result in any effect on the
reactive microglia (Figure 4, FeJ), conﬁrming its speciﬁcity
to metastasis-associated astrocytes. The median numbers of
CD11b/CD45þ microglia cells per section were 111, 113,
and 84.7 for vehicle, 30-mg/kg, and 100-mg/kg pazopanib
treatment groups, respectively (Figure 4F). Collectively, the
data establish the existence of a previously unknown
PDGFRb p751-expressing population of astrocytes in the
cancer metastasis neuroinﬂammatory response in the brain,
which is inhibitable by pazopanib.
Discussion
The brain metastatic process is known to alter the
surrounding microenvironment, changing gene expression,36
producing a neuroinﬂammatory response,22,23,37 and in-
creasing the permeability of the blood-brain barrier to
a limited extent.38e41 However, the molecular characteristics
of these changes, their functional contributions to brain
metastatic colonization, and their effect on therapeutic efﬁ-
cacy remain to be fully understood. With the use of the 231-
BR-HER2 experimental brain metastasis model system, we
ﬁnd that perivascular cancer cell growth involved a remark-
able perturbation of the neurovascular unit, including
increased density of NG2/desmin coexpressing pericytes in
speciﬁc brain microvessels ensheathed by metastatic cellsajp.amjpathol.org - The American Journal of Pathology
Figure 3 Pazopanib inhibited PDGFRb phosphorylation from human immortalized astrocytes and tumor-activated primary cultured human glial in vitro.
A: Microﬂuorimetric image analysis of pazopanib effect on p751-PDGFRb immunostaining (in green) by immortalized human astrocytes cultured in basal
conditions overnight and treated with 5 mmol/L pazopanib (added every 24 hours) or DMSO for 48 hours. p751-PDGFRb staining intensity was quantiﬁed and
normalized to DAPI staining. Data represent average values from ﬁve or seven images per well from three independent experiments (nZ 17 per group). Box-
and-whisker plots of the raw data are shown, but the statistical analysis was performed on transformed data. *P < 0.0001. B and C: Representative images of
p751-PDGFRb staining after DMSO (B) or pazopanib (C) treatments. DeG: Identiﬁcation of PDGFRb phosphorylation in GFAP-expressing cells from a primary
culture of astrocyte-enriched human glial cells. Glial cells were isolated by mechanical cell separation, enzyme digestion, and differential plating, from
a tumor-unaffected area in human brain tissue obtained by neurosurgery from a patient with a metastatic brain tumor. Same antibodies were used as above.
DAPI staining in blue (D). Some p751-PDGFRbeexpressing cells in green (E) and GFAP-expressing cells in red (F) are colocalized in yellow (G). H: Same
enriched glial cell cultures were exposed to basal medium (untreated astrocytes) or the conditioned medium from serum-free and basal condition-cultured
231-BR-HER2 cells (tumor-activated astrocytes) for 18 hours in the presence of 5 mmol/L pazopanib or DMSO. The number of cells expressing p751-
PDGFRb was quantiﬁed by ﬂow cytometry after immunostaining with the same antibody as above. Three independent experiments, using primary culture
from three different patients (n Z 3 per group), are shown in the dot plots. The bars represent the median. Scale bars: 100 mm (B and C); 10 mm (DeG).
PDGFRbþ Astrocytes and Brain Metastasisand perimetastatic accumulation of collagen IV in 40% of
lesions and of reactive glial cells in virtually all metastases.
Reactive glia included microglia coexpressing CD11b/CD45
and astrocytes expressing GFAP. An increase in pericyte
coverage is generally consistent with our previous unantici-
pated observation that more permeable experimental brain
metastases contained vessels decorated with greater
numbers of pericytes.39 In addition to type IV collagen,
perimetastatic deposition of laminin has also been reported
in brain metastases,42 suggesting the deposition of at least
elements of a basement membrane. Type IV collagen
ensheathment of metastases was also heterogeneously re-
ported in a limited study of human tissues.43
Herein, we report that a population of astrocytes in the
neuroinﬂammatory response to 231-BR-HER2 brain metas-
tases expressed p-PDGFRb. The p-PDGFRbþ neuro-
inﬂammatory cells coexpressed GFAP but not NG2, desmin,
or CD11b/CD45. This ﬁnding was conﬁrmed in eight human
craniotomy specimens and in short-term cultures of primary
craniotomy-derived human astrocytes. PDGF and its a andThe American Journal of Pathology - ajp.amjpathol.orgb receptors are well known in the central nervous system but
are mainly characterized in pericyte function in normal
and diseased states29,44,45 and in gliomas.46 A population of
oligodendroglia and their precursors (which can give
rise to astrocyte populations) have been reported to be
PRGDFRaþ47,48 and PDGFRbþ.49 Although we cannot
formally rule out that the cells identiﬁed in the metastasis-
associated neuroinﬂammatory response are oligodendroglia,
their predominance in the gray matter and lack of NG2 pos-
itivity argues against this presumption. The literature about
astrocyte expression of PDGFRs is limited and unclear. In
human brain specimens from patients with ischemic stroke,
PDGRFRmRNA detected by in situ hybridization was robust
in the penumbral astrocytes, although the subtype of receptor
was not determined50; in a mouse staining study, PDGFRb
was undetectable on normal brain astrocytes.29 Astrocytes
and their precursor cells respond to PDGF with a variety of
proliferative and invasive phenotypes,51e53 although it is
impossible to determine whether these responses are direct or
indirect through other cell types present. Together with our2375
Figure 4 Pazopanib induces a decrease in the p751-
PDGFRbeexpressing astrocyte population but does not alter
reactive microglia. Brains, from necropsies of athymic nude
mouse that received231-BR-HER2 cells and vehicle or 30mg/kg
or 100mg/kg pazopanib for 21 days, were ﬁxed, sectioned, and
stained.A: Number of p751-PDGFRbþ astrocytes per highpower
ﬁeld. *P Z 0.023 for vehicle-treated versus 30 mg/kg;
**P Z 0.022 for vehicle-treated versus 100 mg/kg.
B: Percentage of area occupied by p751-PDGFRbþ astrocytes.
yPZ 0.13 for vehicle-treated versus 30mg/kg; yyPZ 0.070 for
vehicle-treated versus 100 mg/kg. Data in A and B were both
determined by photographic analysis of p751-PDGFRb staining.
Raw data are presented, but statistical analysis was performed
on square root transformed data in A and on log10 transformed
data in B. Each dot represents one mouse and is the average of
up to nine groups of metastases. CeE: Representative images
of p751-PDGFRb and CD31 staining: vehicle (C), 30 mg/kg
pazopanib (D), and 100 mg/kg pazopanib (E). Arrows indicate
representative p751-PDGFRbþ astrocytes. F: Number of CD11b/
CD45þ microglia/macrophages per high power ﬁeld. G: Per-
centage of area occupied by CD11b/CD45þ microglia/macro-
phages. Data in F and G were both determined by photographic
analysis of CD11b/CD45 staining, and data were transformed
for ANOVA. Each dot represents onemouse and is the average of
up to three groups of metastases. HeJ: Representative images
of CD11b/CD45þ staining: vehicle (H), 30mg/kg pazopanib (I),
100 mg/kg pazopanib (J). Scale bars: 100 mm (CeE and HeJ).
Gril et aldata, we hypothesize that p-PDGFRb expression by astrocytes
is a hallmark of their aberrant activation in disease states.
Epidermal growth factor receptor has also been found to be
induced in optic nerve astrocytes after injury,54,55 suggesting
that additional molecular alterations may occur as well.
Our experiments suggest the exciting hypothesis that
p-PDGFRb expression by activated astrocytes in brain
metastasis contributes to functional phenotypes. In short-
term primary cultures, astrocyte p-PDGFRb expression was
inducible by tumor-derived soluble factors, suggesting that it
results from a tumoremicroenvironment cross talk similar to
that previously characterized for bone metastasis.56 Pazopa-
nib is a drug with inhibitory activity to vascular endothelial
growth factor receptor, PDGFR, c-kit, and B-Raf, approved
by the Food and Drug Administration. It inhibited
p-PDGFRbþ human immortalized astrocyte proliferation by
50% at concentrations comparable with that of many tumor
cell lines.32,57 In vitro, pazopanib was able to decrease
p-PDGFRb expression in astrocytes both in normal culture
medium and tumor-activated medium. Our previous work
showed the preventive effect of pazopanib on metastasis
outgrowth, directly targeting the tumor cells. Combining
these two studies, pazopanib’s potent efﬁcacy is most likely2376because of its ability to directly attack the metastatic process
on two fronts: the tumor cells and the microenvironment.
Therefore, the decrease in p-PDGFRbþ astrocytes might be
the result of both a direct block of the PDGFRb expressed by
the astrocytes and a decrease in tumor-secreted factors
subsequent to the metastatic outgrowth prevention effect. An
inherent limitation in our studies is that pazopanib, as
a multikinase inhibitor, could modify astrocyte activation
through other, currently undetectable pathways. Astrocytes
have been reported to serve multiple functions in brain
metastasis, including the production of heparanase,58 nitric
oxide,59 and other cytokines24; the stimulation of tumor cell
proliferation60 and chemotherapeutic resistance25; and the
activation of microglia to further amplify the neuro-
inﬂammatory response.61 It will be of interest to determine
whether the astrocytic PDGFRb pathway mediates these or
other additional phenotypes.
The cancer microenvironment is the interface between
cancer cells and pathophysiology of the patient, and a poten-
tially important trend in cancer research is that functional
pathways in the tumor microenvironment may represent
valuable therapeutic targets for more effective cancer treat-
ment. The recent success of targeting cytotoxic T lymphocyteajp.amjpathol.org - The American Journal of Pathology
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metastatic melanoma points to potential clinical success.62
For brain metastasis, several potential therapeutic targets
have been identiﬁed in the microenvironment, including the
heparanase, plasminogen activator, and metalloproteinase
systems.63e65 Herein, we demonstrate that pazopanib treat-
ment of mice signiﬁcantly reduced the percentage of
p-PDGFRbþ astrocytes in the brain in vivo at two doses. In
these same experiments, the development of large brain
metastases was signiﬁcantly prevented. Of the different
chemotherapeutic and molecular drugs that we have tested to
date in the 231-BR model system, pazopanib has been the
most efﬁcacious in prevention of metastatic coloniza-
tion.9,10,66,67 We hypothesize that pazopanib activity resulted
from both tumor and microenvironmental effects. Although
the brain metastasis process in this animal model might
have limitations for a direct clinical translation, our results
show that the newly identiﬁed subpopulation of activated
p-PDGFRbþ astrocytes is playing a key role in the mecha-
nismof brainmicrometastasis progression. However, this was
inhibited by pazopanib, suggesting it is a speciﬁc drug able to
prevent further development of subclinical perivascular
micrometastases.
Supplementary Data
Supplemental material for this article can be found at
http://dx.doi.org/10.1016/j.ajpath.2013.02.043.
References
1. Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P,
Sawaya RE: Incidence proportions of brain metastases in patients
diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer
Surveillance System. J Clin Oncol 2004, 22:2865e2872
2. Stemmler HJ, Heinemann V: Central nervous system metastases in
HER-2-overexpressing metastatic breast cancer: a treatment chal-
lenge. Oncologist 2008, 13:739e750
3. Gril B, Evans L, Palmieri D, Steeg PS: Translational research in brain
metastasis is identifying molecular pathways that may lead to the
development of new therapeutic strategies. Eur J Cancer 2010, 46:
1204e1210
4. Lin NU, Winer EP: Brain metastases: the HER2 paradigm. Clin
Cancer Res 2007, 13:1648e1655
5. Steeg PS, Camphausen KA, Smith QR: Brain metastases as preven-
tive and therapeutic targets. Nat Rev Cancer 2011, 11:352e363
6. Eichler AF, Chung E, Kodack DP, Loefﬂer JS, Fukumura D,
Jain RK: The biology of brain metastases-translation to new thera-
pies. Nat Rev Clin Oncol 2011, 8:344e356
7. Steeg PS: Perspective: the right trials. Nature 2012, 485:S58eS59
8. Palmieri D, Fitzgerald D, Shreeve SM, Hua E, Bronder JL, Weil RJ,
Davis S, Stark AM, Merino MJ, Kurek R, Mehdorn HM, Davis G,
Steinberg SM, Meltzer PS, Aldape K, Steeg PS: Analyses of resected
human brain metastases of breast cancer reveal the association
between up-regulation of hexokinase 2 and poor prognosis. Mol
Cancer Res 2009, 7:1438e1445
9. Palmieri D, Lockman PR, Thomas FC, Hua E, Herring J, Hargrave E,
Johnson M, Flores N, Qian Y, Vega-Valle E, Taskar KS, Rudraraju V,
Mittapalli RK, Gaasch JA, Bohn KA, Thorsheim HR, Liewehr DJ,
Davis S, Reilly JF, Walker R, Bronder JL, Feigenbaum L,The American Journal of Pathology - ajp.amjpathol.orgSteinberg SM, Camphausen K, Meltzer PS, Richon VM, Smith QR,
SteegPS:Vorinostat inhibits brainmetastatic colonization in amodel of
triple-negative breast cancer and induces DNA double-strand breaks.
Clin Cancer Res 2009, 15:6148e6157
10. Gril B, Palmieri D, Bronder JL, Herring JM, Vega-Valle E,
Feigenbaum L, Liewehr DJ, Steinberg SM, Merino MJ, Rubin SD,
Steeg PS: Effect of lapatinib on the outgrowth of metastatic breast
cancer cells to the brain. J Natl Cancer Inst 2008, 100:1092e1103
11. Zhao H, Cui K, Nie F,Wang L, BrandlMB, Jin G, Li F, MaoY, Xue Z,
Rodriguez A, Chang J, Wong ST: The effect of mTOR inhibition alone
or combined with MEK inhibitors on brain metastasis: an in vivo
analysis in triple-negative breast cancer models. Breast Cancer Res
Treat 2012, 131:425e436
12. Paget S: The distribution of secondary growths in cancer of the breast.
Lancet 1889, 1:99e101
13. Condeelis J, Pollard JW: Macrophages: obligate partners for tumor
cell migration, invasion, and metastasis. Cell 2006, 124:263e266
14. Kalluri R, Zeisberg M: Fibroblasts in cancer. Nat Rev Cancer 2006,
6:392e401
15. Fidler I: The pathogenesis of cancer metastasis: the “seed and soil”
hypothesis revisited. Nat Rev Cancer 2003, 3:453e458
16. Vidal-Vanaclocha F: The liver prometastatic reaction of cancer
patients: implications for microenvironment-dependent colon cancer
gene regulation. Cancer Microenviron 2011, 4:163e180
17. Palmieri D, Bronder JL, Herring JM, Yoneda T, Weil RJ, Stark AM,
Kurek R, Vega-Valle E, Feigenbaum L, Halverson D, Vortmeyer AO,
Steinberg SM, Aldape K, Steeg PS: Her-2 overexpression increases
the metastatic outgrowth of breast cancer cells in the brain. Cancer
Res 2007, 67:4190e4198
18. Fitzgerald DP, Subramanian P, Deshpande M, Graves C, Gordon I,
Qian Y, Snitkovsky Y, Liewehr DJ, Steinberg SM, Paltan-Ortiz JD,
Herman MM, Camphausen K, Palmieri D, Becerra SP, Steeg PS:
Opposing effects of pigment epithelium-derived factor on breast
cancer cell versus neuronal survival: implication for brain metastasis
and metastasis-induced brain damage. Cancer Res 2012, 72:144e153
19. Gril B, Palmieri D, Qian Y, Smart D, Ileva L, Liewehr DJ,
Steinberg SM, Steeg PS: Pazopanib reveals a role for tumor cell B-
Raf in the prevention of HER2þ breast cancer brain metastasis. Clin
Cancer Res 2011, 17:142e153
20. Oskarsson T, Acharyya S, Zhang XH, Vanharanta S, Tavazoie SF,
Morris PG, Downey RJ, Manova-Todorova K, Brogi E, Massague J:
Breast cancer cells produce tenascin C as a metastatic niche
component to colonize the lungs. Nat Med 2011, 17:867e874
21. Carbonell WS, Ansorge O, Sibson N, Muschel R: The vascular
basement membrane as “soil” in brain metastasis. PLoS One 2009, 4:
e5857
22. Fitzgerald D, Palmieri D, Hua E, Hargrave E, Herring J, Qian Y, Vega-
Valle E, Weil R, Stark A, Vortmeyer A, Steeg P: Reactive glia are
recruited by highly proliferative brain metastases of breast cancer and
promote tumor cell colonization. Clin Exp Metast 2008, 25:799e810
23. Lorger M, Felding-Habermann B: Capturing changes in the brain
microenvironment during initial steps of breast cancer brain metas-
tasis. Am J Pathol 2010, 176:2958e2971
24. Seike T, Fujita K, Yamakawa Y, Kido MA, Takiguchi S,
Teramoto N, Iguchi H, Noda M: Interaction between lung cancer cells
and astrocytes via speciﬁc inﬂammatory cytokines in the microen-
vironment of brain metastasis. Clin Exp Metastasis 2011, 28:13e25
25. Kim SJ, Kim JS, Park ES, Lee JS, Lin Q, Langley RR, Maya M, He J,
Kim SW, Weihua Z, Balasubramanian K, Fan D, Mills GB, Hung MC,
Fidler IJ: Astrocytes upregulate survival genes in tumor cells and
induce protection from chemotherapy. Neoplasia 2011, 13:286e298
26. Norazit A, Nguyen MN, Dickson CG, Tuxworth G, Goss B, Mackay-
Sim A, Meedeniya AC: Vascular endothelial growth factor and
platelet derived growth factor modulates the glial response to
a cortical stab injury. Neuroscience 2011, 192:652e660
27. Fisher M: Pericyte signaling in the neurovascular unit. Stroke 2009,
40:S13eS152377
Gril et al28. Valenzuela CF, Kazlauskas A, Weiner JL: Roles of platelet-derived
growth factor in the developing and mature nervous systems. Brain
Res Brain Res Rev 1997, 24:77e89
29. Winkler EA, Bell RD, Zlokovic BV: Pericyte-speciﬁc expression of
PDGF beta receptor in mouse models with normal and deﬁcient
PDGF beta receptor signaling. Mol Neurodegener 2010, 5:32
30. Ostman A, Heldin CH: PDGF receptors as targets in tumor treatment.
Adv Cancer Res 2007, 97:247e274
31. Kumar R, Knick VB, Rudolph SK, Johnson JH, Crosby RM,
Crouthamel MC, Hopper TM, Miller CG, Harrington LE, Onori JA,
Mullin RJ, Gilmer TM, Truesdale AT, Epperly AH, Boloor A,
Stafford JA, Luttrell DK, Cheung M: Pharmacokinetic-pharmacody-
namic correlation from mouse to human with pazopanib, a multi-
kinase angiogenesis inhibitor with potent antitumor and
antiangiogenic activity. Mol Cancer Ther 2007, 6:2012e2021
32. Gril B, Palmieri D, Qian Y, Anwar T, Ileva L, Bernardo M,
Choyke P, Liewehr DJ, Steinberg SM, Steeg PS: The B-Raf status of
tumor cells may be a signiﬁcant determinant of both antitumor and
anti-angiogenic effects of pazopanib in xenograft tumor models.
PLoS One 2011, 6:e256k25
33. Sonoda Y, Ozawa T, Hirose Y, Aldape KD, McMahon M,
Berger MS, Pieper RO: Formation of intracranial tumors by geneti-
cally modiﬁed human astrocytes deﬁnes four pathways critical in the
development of human anaplastic astrocytoma. Cancer Res 2001, 61:
4956e4960
34. Diaz-Flores L, Gutierrez R, Madrid JF, Varela H, Valladares F,
Acosta E, Martin-Vasallo P, Diaz-Flores L Jr: Pericytes. Morpho-
function, interactions and pathology in a quiescent and activated
mesenchymal cell niche. Histol Histopathol 2009, 24:909e969
35. Kang SH, Fukaya M, Yang JK, Rothstein JD, Bergles DE: NG2þ
CNS glial progenitors remain committed to the oligodendrocyte
lineage in postnatal life and following neurodegeneration. Neuron
2010, 68:668e681
36. Park E, Kim S, Kim S, Yoon SL, Leem SH, Kim SB, Kim S,
Park YY, Cheong JH, Woo H, Mills G, Fidler I, Lee JS: Cross-
species hybridization of microarrays for studying tumor transcriptome
of brain metastasis. Proc Natl Acad Sci U S A 2011, 108:
17456e17461
37. Zhang M, Olsson Y: Reactions of astrocytes and microglial cells
around hematogenous metastases of the human brain. Expression of
endothelin-like immunoreactivity in reactive astrocytes and activation
of microglial cells. J Neurol Sci 1995, 134:26e32
38. Gerstner E, Fine R: Increased permeability of the blood-brain barrier
to chemotherapy in metastatic brain tumors: establishing a treatment
paradigm. J Clin Oncol 2007, 25:2306e2312
39. Lockman P, Mittapalli R, Taskar K, Rudraruju V, Gril B, Bohn K,
Adkins C, Thomas F, Thorsheim H, Gaasch J, Huang S, Palmieri D,
Steeg P, Smith Q: Heterogeneous blood-brain barrier permeability
determines drug efﬁcacy in mouse brain metastases of breast cancer.
Clin Cancer Res 2010, 16:5662e5678
40. Percy DB, Ribot EJ, Chen Y, McFadden C, Simedrea C, Steeg PS,
Chambers AF, Foster PJ: In vivo characterization of changing blood-
tumor barrier permeability in a mouse model of breast cancer
metastasis: a complementary magnetic resonance imaging approach.
Invest Radiol 2011, 46:718e725
41. Deeken JF,LoscherW:The blood-brain barrier and cancer: transporters,
treatment, and Trojan horses. Clin Cancer Res 2007, 13:1663e1674
42. Castronovo V, Bracke M, Mareel M, Reznik M, Foidart J: Absence of
laminin deposition in breast-cancer and metastases except to the
brain. Pathol Res Pract 1991, 187:201e208
43. McArdle J, Muller H, Roff B,MurphyW: Basal lamina redevelopment
in tumours metastatic to the brain: an immunoperoxidase study using
an antibody to type-IV collagen. Int J Cancer 1984, 34:633e638
44. Arimura K, Ago T, Kamouchi M, Nakamura K, Ishitsuka K,
Kuroda J, Sugimori H, Ooboshi H, Sasaki T, Kitazono T: PDGF
receptor beta signaling in pericytes following ischemic brain injury.
Curr Neurovasc Res 2012, 9:1e9237845. Song N, Huang Y, Shi H, Yuan S, Ding Y, Song X, Fu Y, Luo Y:
Overexpression of platelet-derived growth factor-BB increases tumor
pericyte content via stromal-derived factor-1alpha/CXCR4 axis.
Cancer Res 2009, 69:6057e6064
46. Dai C, Celestino JC, Okada Y, Louis DN, Fuller GN, Holland EC:
PDGF autocrine stimulation dedifferentiates cultured astrocytes and
induces oligodendrogliomas and oligoastrocytomas from neural
progenitors and astrocytes in vivo. Genes Dev 2001, 15:1913e1925
47. Wilson HC, Scolding NJ, Raine CS: Co-expression of PDGF alpha
receptor and NG2 by oligodendrocyte precursors in human CNS and
multiple sclerosis lesions. J Neuroimmunol 2006, 176:162e173
48. Maeda Y, Solanky M, Menonna J, Chapin J, Li W, Dowling P:
Platelet-derived growth factor-alpha receptor-positive oligodendroglia
are frequent in multiple sclerosis lesions. Ann Neurol 2001, 49:
776e785
49. Grinspan JB, Reddy UR, Stern JL, Hardy M, Williams M, Baird L,
Pleasure D: Oligodendroglia express PDGF beta-receptor protein and
are stimulated to proliferate by PDGF. Ann N Y Acad Sci 1990, 605:
71e80
50. Krupinski J, Issa R, Bujny T, Slevin M, Kumar P, Kumar S, Kaluza J:
A putative role for platelet-derived growth factor in angiogenesis and
neuroprotection after ischemic stroke in humans. Stroke 1997, 28:
564e573
51. Nakamura-Ishizu A, Kurihara T, Okuno Y, Ozawa Y, Kishi K,
Goda N, Tsubota K, Okano H, Suda T, Kubota Y: The formation of
an angiogenic astrocyte template is regulated by the neuroretina in
a HIF-1-dependent manner. Dev Biol 2012, 363:106e114
52. Wang HH, Hsieh HL, Yang CM: Calmodulin kinase II-dependent
transactivation of PDGF receptors mediates astrocytic MMP-9
expression and cell motility induced by lipoteichoic acid. J Neuro-
inﬂammation 2010, 7:84
53. Nazarenko I, Hedren A, Sjodin H, Orrego A, Andrae J, Aﬁnk GB,
Nister M, Lindstrom MS: Brain abnormalities and glioma-like lesions
in mice overexpressing the long isoform of PDGF-A in astrocytic
cells. PLoS One 2011, 6:e18303
54. Zhang X, Neufeld A: Activation of the epidermal growth factor
receptor in optic nerve astrocytes leads to early and transient induction
of cyclooxygenase-2. Invest Opthamol Vis Sci 2005, 46:2035e2041
55. Liu B, Chen H, Johns T, Neufeld A: Epidermal growth factor receptor
activation: an upstream signal for transition of quiescent astrocytes
into reactive astrocytes after injury. J Neurosc 2006, 26:7532e7540
56. Mundy G: Metastasis to the bone: causes, consequences and thera-
peutic opportunities. Nat Cancer Rev 2002, 2:584e593
57. Olaussen KA, Commo F, Tailler M, Lacroix L, Vitale I, Raza SQ,
Richon C, Dessen P, Lazar V, Soria JC, Kroemer G: Synergistic
proapoptotic effects of the two tyrosine kinase inhibitors pazopanib
and lapatinib on multiple carcinoma cell lines. Oncogene 2009, 28:
4249e4260
58. Marchetti D, Li J, Shen R: Astrocytes contribute to the brain-
metastatic speciﬁcity of melanoma cells by producing heparanase.
Cancer Res 2000, 60:4767e4770
59. Samdani AF, Kuchner EB, Rhines L, Adamson DC, Lawson C,
Tyler B, Brem H, Dawson VL, Dawson TM: Astroglia induce
cytotoxic effects on brain tumors via a nitric oxide-dependent
pathway both in vitro and in vivo. Neurosurgery 2004, 54:
1231e1237. discussion 1237e1238
60. Sierra A, Price J, Garcia-Ramirez M, Mendez O, Lopez L, Fabra A:
Astrocyte derived cytokines contribute to the metastatic brain speci-
ﬁcity of breast cancer cells. Lab Invest 1997, 77:357e368
61. Zhang M, Olsson Y: Reactions of astrocytes and microglial cells
around hematogenous metastases of the human brain. Expression of
endothelin-like immunoreactivity in reactive astrocytes and action of
microglial cells. J Neurol Sci 1995, 134:26e32
62. Prieto PA, Yang JC, Sherry RM, Hughes MS, Kammula US,
White DE, Levy CL, Rosenberg SA, Phan GQ: CTLA-4 blockade
with ipilimumab: long-term follow-up of 177 patients with metastatic
melanoma. Clin Cancer Res 2012, 18:2039e2047ajp.amjpathol.org - The American Journal of Pathology
PDGFRbþ Astrocytes and Brain Metastasis63. Kruger A, Sanchez-Sweatman OH, Martin DC, Fata JE, Ho AT,
Orr FW, Ruther U, Khokha R: Host TIMP-1 overexpression confers
resistance to experimental brain metastasis of a ﬁbrosarcoma cell line.
Oncogene 1998, 16:2419e2423
64. Maillard C, Bouquet C, Petitjean M, Mesdagt M, Frau E, Jost M,
Masset A, Opolon P, Beermann F, Abitbol M, Foidart J,
Perricaudet M, Noel A: Reduction of brain metastases in plasminogen
activator inhibitor-1 deﬁcient mice with transgenic ocular tumors.
Carcinogenesis 2008, 29:2236e2242
65. Marchetti D, Nicolson G: Human haparanase: a molecular determi-
nant of brain metastasis. Advan Enzyme Regul 2001, 41:343e359The American Journal of Pathology - ajp.amjpathol.org66. Fitzgerald DP, Emerson DL, Qian Y, Anwar T, Liewehr DJ,
Steinberg SM, Silberman S, Palmieri D, Steeg PS: TPI-287, a new
taxane family member, reduces the brain metastatic colonization of
breast cancer cells. Mol Cancer Ther 2012, 11:1959e1967
67. Qian Y, Hua E, Bisht K, Woditschka S, Skordos KW,
Liewehr DJ, Steinberg SM, Brogi E, Akram MM, Killian JK,
Edelman DC, Pineda M, Scurci S, Degenhardt YY, Laquerre S,
Lampkin TA, Meltzer PS, Camphausen K, Steeg PS, Palmieri D:
Inhibition of Polo-like kinase 1 prevents the growth of metastatic
breast cancer cells in the brain. Clin Experimental Metastasis
2011, 28:899e9082379
